A 69-year-old man with left eye pain and visual impairment was diagnosed with syphilitic optic neuritis, who was successfully treated by penicillin. Although it is difficult to decide syphilis as the direct cause of optic neuritis, it is essential to diagnose syphilis in every patient with optic neuritis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020172 | PMC |
| http://dx.doi.org/10.1002/ccr3.5678 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pseudotumoural optic neuritis in myelin oligodendrocyte glycoprotein antibody-associated disease in children: Pseudotumoural optic neuritis in MOG antibody-associated disease.
Arch Pediatr
January 2025
Department of Pediatrics Neurology, Bicêtre Hospital, Public Assistance-Hospitals of Paris, Le Kremlin-Bicêtre, France; Paris Sud-Saclay University, Le Kremlin-Bicêtre, France.
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a neuro-inflammatory condition affecting adults and children. The presentations vary and include acute disseminated encephalomyelitis, optic neuritis or transverse myelitis. Optic neuritis associated with anti-MOG antibodies is typically bilateral, anterior and initially severe but usually resolves quickly and completely.
View Article and Find Full Text PDFInebilizumab treatment in a patient with co-occurring AQP4-IgG positive neuromyelitis optica spectrum disorder and myasthenia gravis: a case report and literature review.
Front Immunol
January 2025
Department of Geriatric Medicine, Affiliated Hospital of Qingdao University, Qingdao, China.
Objective: This study aims to delineate the clinical features underlying the concurrent disease of neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG), and to identify efficacious therapeutic strategies.
Background: NMOSD and MG are uncommon autoimmune diseases that infrequently co-exist. Despite previous reports, a consensus on treating NMOSD concurrent with MG is lacking.
Characteristics of ocular findings of patients with coronavirus disease 2019 in China.
Front Med (Lausanne)
January 2025
Eye Hospital, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Purpose: This study aimed to report the ocular manifestations in individuals with coronavirus disease 2019 (COVID-19) and investigate any correlation between the occurrence of ocular symptoms and systemic symptoms.
Methods: A retrospective electronic survey was conducted among the general public in northern China from December 2022 through February 2023. Inclusion criteria for COVID-19 was confirmed testing positive via a polymerase chain reaction (PCR) test or testing positive for COVID-19 via an antigen kit.
Value of MRI-based radiomics models for predicting visual outcome in patients with MOG-optic neuritis: A preliminary study.
Eur J Ophthalmol
January 2025
Department of Radiology, 3rd Medical Center of Chinese PLA General Hospital, Beijing, China.
Purpose: To investigate the predictive value of MRI-based radiomics models for the recovery of visual acuity after 12 months in patients with acute phase MOG-optic neuritis(MOG-ON).
Materials And Methods: Clinical and MRI imaging data were collected consecutively from January 2021 to April 2022 from patients with acute stage MOG-ON, and the visual acuity of patients were followed up after 12 months. After stratified random sampling, patients were divided into training and test sets, and prediction models based on CE-T1WI, FS-T2WI, and combined CE-T1WI and FS-T2WI were developed.
Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report.
Front Immunol
January 2025
Genentech, Inc., South San Francisco, CA, United States.
Objectives: This case series describes adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab.
Methods: Case information for patients with AQP4-IgG+ NMOSD who received satralizumab for ≥6 months was obtained from US healthcare providers from April 2022 to January 2024. Patient characteristics, examination findings, diagnostic test results, treatment response, and adverse events were recorded.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!